Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 30 | 2024 | 621 | 7.760 |
Why?
|
| Frailty | 4 | 2024 | 98 | 2.820 |
Why?
|
| Kidney Failure, Chronic | 11 | 2024 | 861 | 2.120 |
Why?
|
| Hyperoxaluria, Primary | 6 | 2021 | 12 | 1.790 |
Why?
|
| Living Donors | 6 | 2024 | 111 | 1.720 |
Why?
|
| Pyridoxine | 2 | 2020 | 14 | 1.200 |
Why?
|
| Altruism | 2 | 2024 | 26 | 0.980 |
Why?
|
| Cellular Senescence | 1 | 2024 | 159 | 0.870 |
Why?
|
| Nephrectomy | 1 | 2024 | 172 | 0.860 |
Why?
|
| Aftercare | 1 | 2024 | 145 | 0.860 |
Why?
|
| Kidney Diseases | 5 | 2021 | 477 | 0.850 |
Why?
|
| Graft Rejection | 6 | 2020 | 576 | 0.810 |
Why?
|
| Self Report | 1 | 2024 | 496 | 0.760 |
Why?
|
| Self-Management | 1 | 2022 | 96 | 0.740 |
Why?
|
| Patient Readmission | 1 | 2024 | 364 | 0.740 |
Why?
|
| Vitamin B Complex | 1 | 2020 | 41 | 0.700 |
Why?
|
| Hyperoxaluria | 3 | 2021 | 5 | 0.670 |
Why?
|
| Paraproteinemias | 4 | 2021 | 16 | 0.650 |
Why?
|
| Middle Aged | 25 | 2024 | 25639 | 0.610 |
Why?
|
| Immunoglobulin Light Chains | 4 | 2020 | 27 | 0.600 |
Why?
|
| Graft Survival | 6 | 2018 | 522 | 0.570 |
Why?
|
| Biomarkers | 2 | 2024 | 2933 | 0.570 |
Why?
|
| Waiting Lists | 1 | 2019 | 220 | 0.570 |
Why?
|
| Hypertension | 2 | 2024 | 1274 | 0.560 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 480 | 0.550 |
Why?
|
| Adult | 26 | 2024 | 28732 | 0.540 |
Why?
|
| Prognosis | 9 | 2024 | 4488 | 0.520 |
Why?
|
| Risk Factors | 12 | 2024 | 9902 | 0.520 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 5013 | 0.520 |
Why?
|
| Kidney Function Tests | 4 | 2024 | 126 | 0.520 |
Why?
|
| Kidney | 6 | 2021 | 1340 | 0.510 |
Why?
|
| Amyloidosis | 2 | 2020 | 66 | 0.490 |
Why?
|
| Health Status | 1 | 2017 | 370 | 0.490 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 2013 | 16 | 0.460 |
Why?
|
| Renal Dialysis | 3 | 2021 | 841 | 0.450 |
Why?
|
| Exercise Therapy | 1 | 2015 | 141 | 0.440 |
Why?
|
| Postoperative Care | 1 | 2015 | 291 | 0.430 |
Why?
|
| Arthritis | 1 | 2013 | 80 | 0.420 |
Why?
|
| Humans | 44 | 2024 | 122293 | 0.410 |
Why?
|
| Patient Compliance | 1 | 2015 | 464 | 0.390 |
Why?
|
| Female | 28 | 2024 | 64882 | 0.380 |
Why?
|
| Male | 27 | 2024 | 59520 | 0.380 |
Why?
|
| Prospective Studies | 4 | 2024 | 5963 | 0.370 |
Why?
|
| Aged | 16 | 2024 | 18784 | 0.370 |
Why?
|
| Potassium Channels | 4 | 1999 | 156 | 0.360 |
Why?
|
| Multiple Myeloma | 2 | 2010 | 171 | 0.360 |
Why?
|
| Oxalates | 3 | 2020 | 32 | 0.360 |
Why?
|
| Kidney Calculi | 1 | 2011 | 40 | 0.360 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 3 | 1999 | 34 | 0.350 |
Why?
|
| Urography | 1 | 2010 | 31 | 0.350 |
Why?
|
| Renal Insufficiency | 2 | 2010 | 232 | 0.350 |
Why?
|
| Hypergammaglobulinemia | 1 | 2010 | 11 | 0.350 |
Why?
|
| Renal Artery | 1 | 2010 | 73 | 0.340 |
Why?
|
| Incidental Findings | 1 | 2010 | 123 | 0.320 |
Why?
|
| Postoperative Complications | 3 | 2024 | 2997 | 0.310 |
Why?
|
| Coronary Angiography | 1 | 2010 | 417 | 0.310 |
Why?
|
| Vascular Diseases | 1 | 2010 | 161 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2011 | 2030 | 0.290 |
Why?
|
| Quality of Life | 1 | 2017 | 1913 | 0.290 |
Why?
|
| Calcium Oxalate | 3 | 2021 | 24 | 0.280 |
Why?
|
| Risk Assessment | 3 | 2024 | 3307 | 0.270 |
Why?
|
| Urinary Tract Infections | 1 | 2010 | 289 | 0.270 |
Why?
|
| Young Adult | 7 | 2022 | 8760 | 0.260 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 1822 | 0.260 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2016 | 12 | 0.260 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2007 | 268 | 0.250 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2006 | 244 | 0.220 |
Why?
|
| Transplant Recipients | 2 | 2022 | 210 | 0.220 |
Why?
|
| Survival Analysis | 4 | 2019 | 1468 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2024 | 12044 | 0.210 |
Why?
|
| West Nile Fever | 1 | 2005 | 139 | 0.210 |
Why?
|
| Minnesota | 2 | 2019 | 130 | 0.200 |
Why?
|
| Myocardium | 3 | 2009 | 980 | 0.200 |
Why?
|
| Opportunistic Infections | 2 | 2013 | 78 | 0.190 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2021 | 7 | 0.190 |
Why?
|
| Adenosine Triphosphate | 2 | 1999 | 288 | 0.190 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2020 | 10 | 0.180 |
Why?
|
| Pancreas Transplantation | 1 | 2020 | 36 | 0.180 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 78 | 0.180 |
Why?
|
| Transaminases | 1 | 2020 | 33 | 0.180 |
Why?
|
| Bariatric Surgery | 1 | 2022 | 114 | 0.180 |
Why?
|
| Cost of Illness | 1 | 2021 | 239 | 0.170 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 110 | 0.170 |
Why?
|
| Donor Selection | 1 | 2020 | 52 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 845 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 227 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2022 | 4643 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 1192 | 0.160 |
Why?
|
| Homozygote | 1 | 2020 | 521 | 0.160 |
Why?
|
| Lower Extremity | 1 | 2020 | 178 | 0.160 |
Why?
|
| Allografts | 2 | 2021 | 186 | 0.160 |
Why?
|
| Receptors, Drug | 1 | 1998 | 38 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2020 | 433 | 0.150 |
Why?
|
| Logistic Models | 2 | 2015 | 1772 | 0.150 |
Why?
|
| Isoantibodies | 1 | 2018 | 71 | 0.150 |
Why?
|
| Electrocardiography | 1 | 2023 | 963 | 0.140 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 88 | 0.140 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 135 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2017 | 83 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2022 | 6290 | 0.140 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 190 | 0.140 |
Why?
|
| Physical Fitness | 1 | 2017 | 88 | 0.140 |
Why?
|
| Tissue Donors | 2 | 2018 | 498 | 0.140 |
Why?
|
| Disease Progression | 2 | 2015 | 1990 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 542 | 0.130 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Polyradiculoneuropathy | 1 | 2015 | 6 | 0.120 |
Why?
|
| Sex Factors | 1 | 2019 | 1238 | 0.120 |
Why?
|
| Actigraphy | 1 | 2015 | 41 | 0.120 |
Why?
|
| Sural Nerve | 1 | 2015 | 47 | 0.120 |
Why?
|
| Exercise | 1 | 2020 | 790 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2021 | 15853 | 0.110 |
Why?
|
| Recurrence | 3 | 2016 | 1413 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3301 | 0.110 |
Why?
|
| Encephalitozoon cuniculi | 1 | 2013 | 1 | 0.110 |
Why?
|
| Encephalitozoonosis | 1 | 2013 | 1 | 0.110 |
Why?
|
| Complement C3 | 1 | 2013 | 47 | 0.110 |
Why?
|
| Synovial Fluid | 1 | 2013 | 15 | 0.110 |
Why?
|
| Biopsy | 3 | 2015 | 1246 | 0.110 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 758 | 0.110 |
Why?
|
| Transplantation, Autologous | 2 | 2016 | 300 | 0.100 |
Why?
|
| Incidence | 3 | 2021 | 3018 | 0.100 |
Why?
|
| Registries | 1 | 2019 | 1367 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 3626 | 0.100 |
Why?
|
| Survival Rate | 2 | 2014 | 1997 | 0.100 |
Why?
|
| Age Factors | 1 | 2019 | 2777 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2015 | 1103 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 713 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2020 | 1166 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 300 | 0.090 |
Why?
|
| Echocardiography, Stress | 1 | 2010 | 16 | 0.090 |
Why?
|
| Complement C4b | 1 | 2010 | 5 | 0.090 |
Why?
|
| Capillaries | 1 | 2010 | 70 | 0.090 |
Why?
|
| Plasmapheresis | 1 | 2010 | 29 | 0.090 |
Why?
|
| HLA Antigens | 3 | 2020 | 240 | 0.090 |
Why?
|
| COS Cells | 3 | 1999 | 273 | 0.090 |
Why?
|
| Comorbidity | 2 | 2014 | 1490 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2015 | 1314 | 0.080 |
Why?
|
| Pancreas | 2 | 2020 | 214 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2017 | 1033 | 0.080 |
Why?
|
| Vascular Malformations | 1 | 2010 | 81 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 585 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2008 | 29 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 323 | 0.070 |
Why?
|
| Rabbits | 2 | 1999 | 716 | 0.070 |
Why?
|
| Urogenital Abnormalities | 1 | 2010 | 163 | 0.070 |
Why?
|
| Troponin T | 1 | 2009 | 245 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2010 | 745 | 0.070 |
Why?
|
| Obesity | 2 | 2022 | 2083 | 0.070 |
Why?
|
| Prevalence | 2 | 2010 | 2371 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 322 | 0.060 |
Why?
|
| Histocompatibility Testing | 2 | 2020 | 147 | 0.060 |
Why?
|
| Babesiosis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Blood Donors | 1 | 2005 | 62 | 0.060 |
Why?
|
| Lyme Disease | 1 | 2005 | 32 | 0.060 |
Why?
|
| Head | 1 | 2005 | 101 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 1999 | 2674 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 605 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 3865 | 0.050 |
Why?
|
| Social Networking | 1 | 2021 | 17 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2016 | 659 | 0.050 |
Why?
|
| Umbilical Cord | 1 | 2021 | 55 | 0.050 |
Why?
|
| Travel | 1 | 2021 | 117 | 0.050 |
Why?
|
| Autoantibodies | 2 | 2016 | 418 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1871 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2020 | 65 | 0.040 |
Why?
|
| Social Support | 1 | 2021 | 341 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 2817 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 160 | 0.040 |
Why?
|
| Neoplasms | 1 | 2014 | 2753 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 428 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1999 | 98 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 1999 | 67 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 443 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 186 | 0.040 |
Why?
|
| Sulfonylurea Receptors | 1 | 1998 | 12 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1998 | 153 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 18940 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 1999 | 408 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 581 | 0.040 |
Why?
|
| Mutagenesis | 1 | 1999 | 351 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 229 | 0.040 |
Why?
|
| BK Virus | 1 | 2018 | 58 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 1999 | 191 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1999 | 272 | 0.030 |
Why?
|
| Child | 2 | 2014 | 24063 | 0.030 |
Why?
|
| Antibodies | 1 | 1998 | 371 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 62 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 768 | 0.030 |
Why?
|
| Kinetics | 1 | 1998 | 1315 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1998 | 523 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 646 | 0.030 |
Why?
|
| Animals | 4 | 2021 | 33721 | 0.030 |
Why?
|
| Proteinuria | 1 | 2015 | 110 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 239 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 1999 | 808 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1118 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 107 | 0.030 |
Why?
|
| Spores, Fungal | 1 | 2013 | 14 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 1001 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 872 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2013 | 157 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 330 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 221 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 1999 | 1520 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1283 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 645 | 0.020 |
Why?
|
| Cadaver | 1 | 2010 | 132 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6182 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2080 | 0.020 |
Why?
|
| Survivors | 1 | 2010 | 345 | 0.020 |
Why?
|
| Sinus of Valsalva | 1 | 2007 | 36 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2007 | 42 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 1090 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 440 | 0.010 |
Why?
|
| Calcium | 2 | 1999 | 1095 | 0.010 |
Why?
|
| Glycosyltransferases | 1 | 1999 | 25 | 0.010 |
Why?
|
| Postprandial Period | 1 | 1999 | 75 | 0.010 |
Why?
|
| Pinacidil | 1 | 1998 | 2 | 0.010 |
Why?
|
| C-Peptide | 1 | 1999 | 108 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1998 | 169 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1998 | 95 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1999 | 212 | 0.010 |
Why?
|
| Pancreatectomy | 1 | 1999 | 135 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 1999 | 173 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 1998 | 86 | 0.010 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1998 | 144 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2000 | 1227 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 1076 | 0.010 |
Why?
|
| Syndrome | 1 | 1999 | 1109 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1370 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1999 | 941 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1998 | 798 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 3074 | 0.010 |
Why?
|
| Mutation | 1 | 1999 | 5734 | 0.000 |
Why?
|